Open AccessRamucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non–Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2
Author(s) -
Richard S. Finn,
Thomas Yau,
ChihHung Hsu,
Enrico N. De Toni,
Lipika Goyal,
Peter R. Galle,
Shukui Qin,
Sujata Rao,
Fangfang Sun,
Chunxiao Wang,
Ryan C. Widau,
Andrew X. Zhu
Publication year - 2022
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1093/oncolo/oyac183
Subject(s) - medicine , ramucirumab , sorafenib , hepatocellular carcinoma , adverse effect , gastroenterology , clinical endpoint , cohort , oncology , surgery , chemotherapy , clinical trial
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom